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radiation doses during adjuvant left-sided
breast cancer radiotherapy
Tanja Skyttä1*, Suvi Tuohinen2, Eeva Boman3, Vesa Virtanen2, Pekka Raatikainen4 and Pirkko-Liisa Kellokumpu-Lehtinen1Abstract
Background: Adjuvant radiotherapy (RT) for left-sided breast cancer increases cardiac morbidity and mortality. For
the heart, no safe radiation threshold has been established. Troponin T is a sensitive marker of myocardial damage.
Our aim was to evaluate the effect of left-sided breast cancer RT on serum high sensitivity troponin T (hscTnT) levels
and its association with cardiac radiation doses and echocardiographic parameters.
Methods: A total of 58 patients with an early stage, left-sided breast cancer or ductal carcinoma in situ (DCIS) who
received adjuvant breast RT without prior chemotherapy were included in this prospective, non-randomized study.
Serum samples were taken before, during and after RT. An increase of hscTnT >30 % was predefined as significant.
A comprehensive 2D echocardiograph and electrocardiogram (ECG) were performed before and after RT. Dose-volume
histograms (DVHs) were generated for different cardiac structures.
Results: The hscTnT increased during RT from baseline in 12/58 patients (21 %). Patients with increased hscTnT values
(group A, N = 12) had significantly higher radiation doses for the whole heart (p = 0.02) and left ventricle (p = 0.03) than
patients without hscTnT increase (group B, N = 46). For the left anterior descending artery (LAD), differences between
groups A and B were found in volumes receiving 15 Gy (p = 0.03) and 20 Gy (p = 0.03) Furthermore, after RT, the
interventricular septum thickened (p = 0.01), and the deceleration time was prolonged (p = 0.008) more in group
A than in group B.
Conclusions: The increase in hscTnT level during adjuvant RT was positively associated with the cardiac radiation
doses for the whole heart and LV in chemotherapy-naive breast cancer patients. Whether these acute subclinical
changes increase the risk of excessive long-term cardiovascular morbidity or mortality, will be addressed in the
follow-up of our patients.
Keywords: Radiotherapy, Breast cancer, Cardiotoxicity, High sensitivity cardiac troponin TBackground
Postoperative radiotherapy (RT) for breast cancer is an
essential part of adjuvant cancer treatment. RT reduces
the risk of local recurrence by 50 % and the risk of
breast cancer mortality by 16 % [1]. However, left-sided
RT, especially, has been shown to induce excess cardio-
vascular mortality and morbidity [1–4]. In a retrospect-
ive study, Darby et al. showed that the risk of major
cardiac events in patients with left-sided breast cancer* Correspondence: tanja.skytta@pshp.fi
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creativecommons.org/publicdomain/zero/1.0/increased by 7.4 % for each increase of 1 Gy of radiation
to the heart. Furthermore, prior cardiovascular diseases,
such as hypertension, may further increase the risk of
radiation induced cardiac damage [4].
Radiation induced cardiac changes have been demon-
strated with echocardiographic strain rate imaging [5],
myocardial perfusion scintigraphy [6, 7] and single photon
emission tomography [8]. In contrast, no changes in the
left ventricle (LV) systolic function were detected in basic
echocardiographic measurements [5, 7]. Majority of pa-
tients in these studies also received prior or concurrent
chemotherapy [5–8], which is known to be associated with
cardiotoxicity [9, 10]. High sensitivity cardiac troponin Tticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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ing RT [5, 11]. The mechanism of this acute damage is
thought to evolve from negative changes in the microvas-
culature during RT [12].
In this study, we included only chemotherapy-naive
breast cancer patients to exclude chemotherapy-
induced prior cardiotoxicity. The patients were studied
prospectively using a cardiac biomarkers, comprehen-
sive 2D echocardiography and 12-lead electrocardio-
gram (ECG) before and after adjuvant RT to detect
subclinical cardiac changes. Furthermore, dose volume
histograms (DVHs) for different cardiac structures were
generated and correlated with serum markers and
echocardiographic measurements.
Methods
Patient population
This single centre, prospective, observational clinical study
included 60 eligible female patients with early stage left-
sided breast cancer or DCIS. All patients were treated with
adjuvant conformal 3D RT after breast conserving surgery
(n = 59) or mastectomy (n = 1) without axillary or supra-
clavicular lymph node RT. Two patients were excluded
from final analysis due to missing serum samples. Patients
with prior adjuvant chemotherapy were excluded. Other
exclusion criteria were age over 80 years, dialysis, recent
acute myocardial infarction, symptomatic heart failure,
chronic atrial fibrillation, pacemaker therapy and severe
lung disease. The local ethical committee approved the
protocol and all participants signed informed consent be-
fore study enrollment. The study was conducted from
June 2011 to May 2013.
Radiation therapy
All patients had 3D computer tomography (CT) treatment
planning with Philips Big Bore CT (Phillips Medical Sys-
tems, Madison, WI, USA) or Toshiba Aquilion LB
(Toshiba Medical System, Tokyo, Japan) on a breast board
in the supine position with their arms above their heads.
CT slices (3 mm thickness) were used without intravenous
contrast. Scanning was performed during free breathing in
56 patients, whereas 2 patients were scanned and treated
using the voluntary deep inspiration breath hold (vDIBH)
technique, which was implemented in our unit in April
2013 as part of clinical practice. In vDIBH, the breathing
cycle was monitored with Varian real time position man-
agement (RPM) system (Varian Medical Systems, Palo
Alto, CA, USA). Treatment contouring and planning were
done with Eclipse v.10 system (Varian Medical Systems,
Palo Alto, CA, USA). Planning target volume (PTV) cov-
ered the remaining breast tissue in 57 patients and the
chest wall in one patient (mastectomy) with sufficient
margins to account for the inter- and intrafraction move-
ments (5–8 mm in our unit).Treatment doses were either 50 Gray (Gy) in 2 Gy frac-
tions with or without additional boost (10–16 Gy, 5–8
fractions) to tumor bed or 42.56 Gy in 2.66 Gy fractions
(hypofractionation) over 3.5 weeks. Tangential photon
fields were used in 57 patients and chest wall in one
patient with mastectomy was treated with electron beams.
Doses were calculated with anisotropic analytical algo-
rithm (AAA v.10, Varian Medical Systems, Palo Alto, CA,
USA) for photons and Electron Monte Carlo algorithm
(eMC v.11, Varian Medical Systems, Palo Alto, CA, USA)
for electrons. Dose volume histograms (DVH) of different
structures were generated for each patient. To account for
the different dosing schedules, an α/β-ratio of 3 was used
for heart and lung to calculate 2 Gy equivalent doses.
The heart, LV and LAD were contoured from the
treatment planning CT scans as suggested by Feng et al.
[13]. All cardiac structures were contoured by the same
radiation oncologist (TS).
Serum biomarker analysis
High sensitivity cardiac troponin T (hscTnT, ng/l) and B-
type natriuretic peptide (BNP, ng/l) were analyzed from
serum samples taken before, after two (hypofractionated
RT) or three (conventional RT) weeks of treatment and at
the last day of RT. As the lowest detection limit of hscTnT
was 5 ng/l, the values below this (<5 ng/l) were estimated
to be 4 (lowest detection limit (LOD)/√2) when calculating
the percentage increase from the baseline value [14]. A
predefined increase of >30 % from the baseline was con-
sidered to be clinically important according to the study
protocol. The patients were divided into two groups based
on their hscTnT change: group A with a hscTnT increase
more than 30 % from baseline during RT and group B
without a hscTnT increase.
Total cholesterol levels (mmol/l) were measured at
baseline under fasting conditions.
Echocardiographic examinations
A comprehensive echocardiography study and 12-lead
ECG were performed at the baseline and at the comple-
tion of RT. All echocardiography examinations were per-
formed using the same ultrasound machine (Philips iE33
ultrasound system, Bothell, WA, USA) and a 1–5 MHz
matrix-array X5-1 transducer by the same cardiologist cer-
tified by European Association of Echocardiography for
adult transthoracic echocardiography. All images were
acquired at rest. Subcostal imaging was performed in the
supine position, while other imaging was performed with
the patient in the lateral decubitus position with simultan-
eous superimposed ECG. Doppler recordings were
acquired at the end of expiration during shallow breathing.
Images were stored digitally for use with offline analysis
software (Excelera, Philips, Koninklijke, Netherlands; Qlab,
Philips, Bothell, USA). Echocardiographic measurements
Table 1 Patient baseline characteristics. Results are presented as
mean ± SD for normally distributed continuous variables,
median (inter-quartile range) for non-normal variables and n (%)
for categorical variables
All
(N = 58)
Group A
(N = 12)
Group B
(N = 46)
p-value*
Age 63 ± 6 65 ± 6 63 ± 7 0.37
BMI, kg/m2 27 ± 4 27 ± 5 27 ± 4 0.76
Hypertension 20 (34 %) 6 (50 %) 14 (30 %) 0.31
ACE or ARB 14 (24 %) 4 (33 %) 10 (22 %) 0.46
Beta-blocker 7 (17 %) 3 (25 %) 4 (9 %) 0.15
Calcium channel
blocker
4 (7 %) 2 (17 %) 2 (4 %) 0.19
CAD 1 (2 %) 0 (0 %) 1 (2 %) 1.00
Statin use 13 (22 %) 3 (25 %) 10 (22 %) 1.00
Diabetes 4 (7 %) 1 (8 %) 3 (7 %) 1.00
Hypothyreosis 8 (14 %) 0 (0 %) 8 (17 %) 0.19
Current smoking 8 (14 %) 2 (17 %) 6 (13 %) 0.66
Hormonal therapy 23 (40 %) 4 (33 %) 19 (41 %) 1.00
AI 22 (38 %) 5 (42 %) 17(37 %) 0.75
Tamoxifen 2 (3 %) 0 (0 %) 2 (4 %) 1.00
Troponin T, ng/l 4 (4–6) 4(4–4.5) 4 (4–7)
Cholesterol, mmol/l 5.6 ± 1.1 5.5 ± 0.9 5.6 ± 1.1 0.90
BNP, ng/l 58 (37–124) 78 (33–123) 58 (41–125) 0.72
BMI body mass index, ACE angiotensin converting enzyme, ARB angiotensin II
receptor blockers, CAD coronary artery disease, Statin use
hypercholesterolemia with statin use, Diabetes blood glucose lowering diabetic
medication, ASA low dose daily acetylsalicylic acid, Hypothyreosis continuous
thyroid hormone supplementation, AI aromatase inhibitor, BNP b-type
natriuretic peptid
* Independent samples t-test was used for normally distributed variables and
Mann–Whitney U test for non-normal variables; Fisher’s exact test was used for
categorical variables
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the European guidelines [15].
Statistical analysis
Data are expressed as means ± standard deviation (SD)
for normally distributed continuous variables and as me-
dians with inter quartile range (IQR) for variables with
non-normal distributions. The study groups were com-
pared using the t-test for independent samples or the
Mann–Whitney U test. Friedman’s analysis of variance
was used for repeated measures of non-normal variables
and the Wilcoxon signed ranks test was used to compare
the hscTnT before RT vs. hscTnT after RT. Categorical
data are expressed as numbers (%) of subjects. The Chi-
squared test was used for categorical variables and the
Fisher’s exact test was used when appropriate. The re-
lated samples Cochran’s Q test was used to study the
change in dichotomous variables measures more than
twice. Area under curve (AUC) was calculated using the
trapezium rule in order to summarize the information
from DVH. All the tests were two-sided and a p value
<0.05 was considered statistically significant. Analysis
was performed using IBM SPSS Statistics for Windows
(version 21.0, Armonk, NY, USA, IBM Corp.).
Results
Baseline characteristics of the patients are presented in
Table 1. The baseline variables (e.g. age, body mass
index, cholesterol and hormonal use) were similar be-
tween the two groups A and B based on the troponin in-
crease. However, in the group A patients tended to have
more hypertension (p = 0.31) and less thyroid hormone
supplementation (p = 0.19).
High sensitivity cardiac troponin T
In the whole study population, hscTnT was detectable
(≥5 ng/l) in 25 (43 %) patients before RT, in 28 (48 %) at
3 weeks and in 30 (52 %) patients after RT. The serum
samples after RT were taken at the last day of RT (me-
dian 0, range −1 − +3 day).
Median (IQR) hscTnT for the whole study population
was 4 (4–6) ng/l before RT, 4 (4–6) ng/l at 3 weeks and
5 (4–7) ng/l after RT. The difference in hscTnT level be-
fore RT and after RT was not significant for the whole
population (p = 0.08). However, hscTnT increased over
30 % from the baseline value in 12/58 (21 %) patients
constituting the group A. In these 12 patients, hscTnT
was detectable in 3 (25 %) before RT, in 9 (75 %) at 2–3
weeks and in 12 (100 %) patients after RT. The median
(IQR) values at these time points were 4 (4–4.5)ng/l, 5.5
(4.5-6)ng/l and 7 (7–9.5)ng/l, respectively (Fig. 1). In the
hscTnT stable group B (N = 46,) hscTnT was detectable
in 22 (48 %) at the beginning, 19 (41 %) at 2–3 weeksand 18 (39 %) after RT with median (IQR) values of
4(4–7), 4(4–6) and 4(4–6) ng/l, respectively.
B-type natriuretic peptide
In the whole study population BNP levels were 58 (37–
124), 69 (42–135) and 74 (34–126) mmol/l before RT, at
2–3 weeks and after RT, respectively (p = 0.72). The BNP
change between the first and the last time point was −5
(−26 to 5) mmol/l in the group A vs. 5 (−14 to 22) mmol/l
in the group B (p = 0.33).
Cardiac doses
The DVH curves for the both groups are presented in
Fig. 2. The AUC for heart and left ventricle was signifi-
cantly higher in the hscTnT-positive group A compared
with group B (p < 0.05, Table 2). The same trend was
seen for the LAD (p = 0.08). In addition to AUC, some
relevant dose-volume parameters (volume of structure
receiving 5 Gy radiation dose = V5 and similarly V10,
V15, V20 and V30) were separately tested (Fig. 2 and
Fig. 1 Box plot figures to describe high sensitivity cardiac troponin T (hscTnT) before RT, at weeks 2–3 and after RT in patients with increased
hscTnT release (Group a, N = 12) and in patients without hscTnT release (Group b, N = 46). Borders of the box represent the upper and lower
quartiles, bold lines the medians and error bars above and below the box represent the 90th and 10th percentiles
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between groups was significant in all those Gy points
from 5 to 20 Gy, but in the LAD the difference between
groups was significant only at dose levels of 15 and
20 Gy.
Echocardiographic findings
In group A, the increase in hscTnT was accompanied by
minor changes in the echocardiographic measurements as
presented in Table 3. Measured before and after RT, the
interventricular septum thickened (p = 0.01) accompanied
with a change in LV diastolic function as the deceleration
time increased (p = 0.008) among group A more than in
group B. In other LV diastolic parameters, the mitral E-
peak decreased in both groups. The decrease in the LV
end diastolic and end systolic diameters in the group A
were not statistically significant compared with group B
(p = 0.06 and p = 0.11, respectively).
ECG
Normal sinus rhythms were present in all ECG record-
ings with no signs of atrial or ventricular abnormalities.
RT caused moderate T-wave alterations in 3/12 (25 %)
recordings among group A and 13/46 (28 %) among
group B (p = 0.82).
Discussion
We demonstrated that high sensitivity cardiac troponin
T levels increased during the whole breast adjuvant RT
in every fifth patient. In addition, the increase in the
hscTnT release associated positively with cardiac radi-
ation doses and with minor changes in LV’s measure-
ments suggesting that RT caused subclinical myocardial
damage.High sensitivity cardiac TnT release
Cardiac troponin T is a well-established biomarker of
cardiac damage in myocardial infarction due to ischemic
heart disease. Moreover, it can detect cardiac damage in
other clinical conditions such as heart failure [16, 17]
and LV hypertrophy [18, 19]. The hscTnT values in
healthy individuals have varied in different studies. The
99th percentile differed from 12 ng/l [20] to 20 ng/l [21]
and is largely shown to be influenced by patient’s age,
gender and comorbidities [22]. By excluding patients
with underlying cardiac diseases, it is estimated that the
median values (IQR) of hscTnT for women <55 years as
well as <75 years are <3 (<3 - < 3) ng/l and the upper
normal 99th percentile limit is 3.4 ng/l for women
<55 years and 11.4 ng/l for women <75 years [22]. The
weekly within person variation of hscTnT in healthy in-
dividuals is estimated to be 8 % [23] -32 % [24]. Diurnal
changes in hscTnT are also observed with a decline in
values by 0.8 % per hour from 8:30 to 14:30 [23]. Based
on these results, a relevant increase in hscTnT levels
during RT was predefined to exceed 30 % from individ-
ual baseline in this study. In our patients, the serum
samples at the baseline and at the end of the RT were
taken in the morning within a 2 h maximum time differ-
ence in 55 patients. In the remaining three patients (all
in the group B), the time difference was 2.1, 4 and 5 h.
The hscTnT levels in the group A increased 40 %–325 %
from baseline and, therefore, the change cannot be
explained by normal weekly or diurnal variation.
In cancer patients, elevated troponin T and I levels
have been reported after various chemotherapy regimens
[25–27]. In addition, the elevation of TnT during or
shortly after chemotherapy correlated with long term
negative changes in echocardiography [25, 27]. The
Fig. 2 Dose volume histogram (DVH) curves for left anterior
descending artery (LAD), heart and left ventricle (LV) in patients
with increased high sensitivity cardiac troponin T (hscTnT) release
(Group A, N = 12) and in patients without hscTnT release (Group
B, N = 46)
Table 2 Radiation doses to cardiac structures in patients with
hscTnT increase >30 % from baseline during RT (Group A) vs.
patients without hscTnT increase (Group B)
Cardiac structure Group A (N = 12) Group B (N = 46) p value*
Heart
Dmean (Gy) 4.0 ± 1.8 2.8 ± 1.3 0.02
Dmax (Gy) 48.9 ± 5.3 43.9 ± 11.0 0.13
V5 (%) 12.0 ± 6.2 8.1 ± 4.6 0.02
V10 (%) 8.4 ± 5.1 4.9 ± 3.4 0.01
V15 (%) 7.1 ± 4.4 4.0 ± 3.1 0.01
V20 (%) 5.7 ± 3.3 3.5 ± 2.8 0.02
V30 (%) 4.0 ± 2.6 2.6 ± 2.3 0.08
AUC (%.Gy) 403 ± 172 291 ± 134 0.02
LV
Dmean (Gy) 6.7 ± 3.3 4.5 ± 2.6 0.02
Dmax (Gy) 47.8 ± 5.8 41.0 ± 12.2 0.07
V5 (%) 22.0 ± 12.3 14.5 ± 9.2 0.02
V10 (%) 15.5 ± 10.2 8.6 ± 7.0 0.01
V15 (%) 13.2 ± 9.2 7.2 ± 6.4 0.01
V20 (%) 11.1 ± 7.7 6.2 ± 5.9 0.02
V30 (%) 7.1 ± 5.4 4.4 ± 4.7 0.10
AUC (%.Gy) 668 ± 333 468 ± 260 0.03
LAD
Dmean (Gy) 23.8 ± 10.1 17.5 ± 10.8 0.07
Dmax (Gy) 43.4 ± 11.8 37.9 ± 15.8 0.27
V5 (%) 68.3 ± 24.2 61.7 ± 24.1 0.40
V10 (%) 61.9 ± 26.1 45.7 ± 27.7 0.07
V15 (%) 58.6 ± 26.3 40.0 ± 28.0 0.047
V20 (%) 55.4 ± 26.3 36.2 ± 28.3 0.04
V30 (%) 45.0 ± 25.3 29.3 ± 27.8 0.08
AUC (%.Gy) 2422 ± 1053 1793 ± 1097 0.08
hscTnT high sensitivity cardiac troponin T, RT radiotherapy, Dmean mean
radiation dose to the structure, Dmax maximal point radiation dose in the
structure, V30/20/10/5 the volume of structure receiving 30Gy/20Gy/10Gy/5Gy
dose, AUC area under the curve, LV left ventricle, LAD left anterior descending
coronary artery
*Independent samples t-test
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not detected in earlier studies with less sensitive tropo-
nin methods [28, 29]. In a study by Nellessen et al. [11],
thoracic RT for breast or lung cancer in 23 patients in-
creased troponin levels measured during and at the end
of RT. It is, however, noteworthy that the majority (16/
23) of these patients had received prior chemotherapy.
Our patients were, as described earlier, previously un-
treated by chemotherapy. Therefore, these observed
changes represent the radiation induced damage to myo-
cardium. The RT-induced harmful process in the heart
is thought to evolve from the clotting of myocardial
microvessels and the subsequent hypoxia leading to
myocyte damage [12]. The absolute levels of hscTnT at
the end of RT in our patients were below the clinically
used threshold for myocardial infarction (50 ng/l).Nevertheless, measurable (>4 ng/l) troponin levels indi-
cate worse cardiac long term prognosis in other clinical
conditions [17, 18].
Cardiac radiation doses
In the previous studies, the mean cardiac radiation dose
has varied from 4.9 Gy (retrospective analysis) [4] to
9 Gy (prospective analysis) [5]. In our study, the mean
heart dose in the group A was significantly higher (4.0 ±
1.8 Gy) than in the group B (2.8 ± 1.4 Gy). As presented
in Table 2 and Fig. 2, also the measured dose-volume
points for the whole heart were significantly different be-
tween the groups. In group A, larger volumes of the
Table 3 Echocardiographic measurements at baseline(before RT) and the change from baseline measured at the end of RT in
patients with increased hscTnT release (group A) and in patients without hscTnT release (group B)
Group A (N = 12) Group B (N = 46)
Before RT Change Before RT Change P*
LV dimensions
LVEDD (mm) 44.0 (42.0 - 45.5) -2.0 (-3.5 - 0.0) 46.0 (44.0 - 47.0) -0.5 (-2.0 - 2.0) 0.06
LVESD (mm) 30.0 (27.5 - 31.0) -1.5 (-4.5 - 1.5) 31.0 (29.0 - 33.0) 0.0 (-2.0 - 2.0) 0.11
IVS (mm) 11.0 (8.5 - 11.5) 1.0 (0.0 - 1.0) 10.0 (9.0 - 11.0) 0.0 (0.0 - 1.0) 0.01
PW (mm) 10.0 (9.5 - 11.0) 1.0 (0.0 - 1.0) 10.0 (9.0 - 11.0) 0.0 (-1.0 - 1.0) 0.50
RV functions
Tapse (mm) 23.5 (21.0 - 25.0) -1.0 (-3.5 - 0.5) 24.5 (21.0 - 28.0) -2.0 (-4.0 - 0.0) 0.63
RV s’ (cm/s) 11.3 (9.5 - 14.1) -0.2 (-0.6 - 1.5) 12.0 (10.3 - 13.2) -0.5 (-1.4 - 0.7) 0.34
RV Ee’ ratio 4.2 (3.3 - 5.0) 0.7 (-1.6 - 2.5) 3.9 (3.3 - 4.9) 0.1 (-0.3 - 0.8) 0.88
LV functions
EF (%) 62.5 (60.0 - 64.5) 1.5 (-4.5 - 3.5) 62.0 (58.0 - 65.0) 0.0 (-4.0 - 4.0) 0.87
Mitral E (cm/s) 68.8 (58.5 - 79.0) -4.3 (-6.0 - 0.3) 74.0 (64.7 - 84.8) -3.8 (-10.8 - 3.9) 0.94
Dt (ms) 204 (192 - 236) 32 (9–64) 230 (208 - 261) 0 (-29 - 21) 0.008
EA ratio 0.8 (0.7 - 0.9) 0.0 (-0.1 - 0.1) 1.0 (0.8 - 1.1) 0.0 (-0.1 - 0.1) 0.99
IVRT (ms) 113 (89 - 122) 3 (-6 - 21) 103 (90 - 123) 4 (-10 - 21) 0.92
Ee’ ratio 8.9 (6.9 - 10.9) 0.6 (-2.0 - 1.5) 9.3 (7.4 - 10.6) -0.3 (-1.4 - 0.6) 0.30
LV left ventricle, LVEDD left ventricular end diastolic diameter, LVESD left ventricular end systolic diameter, IVS interventricular septum thickness, PW thickness of
left ventricle’s posterior wall, RV right ventricle, tapse tricuspid annular plane systolic excursion, RV’s systolic tissue doppler measurement of right ventricle’s free
wall, RV Ee’ratio the ratio of early tricuspid inflow to annular diastolic velocity, EF ejection fraction, Mitral E first peak of diastole, active filling, Dt deceleration time
during diastole, EA ratio ratio of diastolic peaks E and A, IVRT isovolumic relaxation time, Ee’ratio ratio of early transmitral flow velocity (E) to early diastolic velocity
of the mitral valve annulus (e)
*p value between groups
Skyttä et al. Radiation Oncology  (2015) 10:141 Page 6 of 8cardiac structures received more radiation. These find-
ings show, that increasing cardiac doses associate with
myocyte damage measured by hscTnT release. In animal
models, even doses as low as 2 Gy for the whole heart
induced cardiac remodelling and fibrinogenesis [30]. In a
retrospective study on breast cancer patients, the risk of
major cardiac event increased linearly with every in-
creasing Gy for the heart [4]. Absolutely safe cardiac
doses cannot be extrapolated either from our results or
from previous data. Furthermore, it is still unclear,
whether a low dose for a larger cardiac volume is more
detrimental than a higher dose for a smaller volume.
However, our DVH data suggest that if the mean dose
for the whole heart is under 2 Gy at least the risk of
acute myocyte damage is low. This can easily be reached
in majority of node-negative patients, if vDIBH (own
institutional experience) or Active Breathing Control
(ABC) [31] is utilized.
Increasing doses to LV correlate with myocardial per-
fusion defects [6, 7, 32]. In our patients, the mean dose
to LV was higher in the group A and the difference in
V5 Gy, V10 Gy and V20 Gy was also significant.
The LAD runs in the sulcus between the left and right
ventricle. Its anatomical location in relation to chest wall
varies from one patient to another. The LAD is, however,generally at the most anterior part of the LV and therefore,
the radiation doses to LAD in left sided breast cancer RT
can be substantial. In coronary vessels, the acute RT
induced damage may later manifest as thickening and
fibrosis of the vessel walls and increased local atheroscler-
osis. The coronary arteries should be considered as a
serial-type organ, where the damage to one small part
affects the function of whole the unit. In our patients, the
DVHs of the LAD differ clearly after 5 Gy and converge
only at high doses. The AUC analysis of the LAD did not
reach statistical significance due to variation of doses and
the limited number of patients.
Echocardiographic changes
LV’s ejection fraction (LVEF), a widely used marker of
the LV’s systolic function in oncology, did not decrease
in our patients after RT. This finding is similar than with
Lo Q et al. [33], who detected subclinical cardiac dys-
function by 2-D strain imaging in LV after left-sided
breast cancer RT, but LVEF remained unchanged. In
addition, LVEF can remain within normal limits even in
a presence of significant cardiac diastolic dysfunction.
This entity of heart failure with preserved ejection frac-
tion (HFpEF) is more common in elderly women and it
is thought to have a multi-factorial etiology [34, 35]. It
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duced heart disease such as increased fibrosis markers
[36] and proinflammatory changes [37].
Diastolic changes in LV’s function were observed in
both groups such as lower mitral E peak. As RT induces
inflammation and later fibrinogenesis in tissues [12], it is
logical that the early cardiac changes would be first
present in the diastole, where the impaired relaxation
and increased stiffness in ventricular walls cause im-
paired filling. The prolongation of diastolic deceleration
time, a representative of increased ventricular wall stiff-
ness, was apparent after RT in group A accompanied
with increased septum thicknesses in contrast to group
B. In addition, the LV diameters in both end systole and
diastole decreased more in group A than group B- yet
this failed to reach statistical significance due to small
number of patients. Diastolic dysfunction can cause
major cardiac morbidity such as dyspnea in mild exer-
tion, fatigue and fluid retention [38]. These findings
further support the value of troponin release as a simple
marker of radiation-induced myocardial damage.
Confounding factors and limitations
Hypertension is a known additive risk factor for RT
induced cardiotoxicity [4]. In our patients, 50 % of the
group A patients had hypertension compared with 30 %
in the group B. However, this difference was not signifi-
cant. It is of interest, that none of the patients using thy-
roid hormone supplementation had increases in hscTnT
levels. There is experimental data on the benefits of
thyroid hormone use after myocardial infarction (MI) in
rodents [39, 40], and the beneficial effects of high T3
levels on cardiac functions after MI have been described
also in humans [41]. This finding is intriguing and
should be validated in a larger population as no reliable
and clinically relevant subgroup analysis could be per-
formed in our study due to the relatively small number
of patients.
Clinical implications
HscTnT is a sensitive marker of acute myocardial dam-
age. In general, greater damage causes a greater troponin
release and indicates worse prognosis. In this study, the
increases in hscTnT values associated with increased
cardiac radiation doses for the whole heart and LV. In
daily RT treatment planning, at least the whole heart
should be contoured as an organ at risk for left sided
breast cancer RT in order to keep the cardiac dose as
low as possible. Evolving radiation techniques will help
to accomplish the cardiac dose sparing. Patient derived
risk factors, such as hypertension, are still important and
need special caution and guidance. Echocardiography
can measure RT induced subclinical cardiac changes im-
mediately after breast cancer RT and should be used inthe later follow up of patients. Likewise, an expert con-
sensus from 2013 recommends routine echocardiog-
raphy after left sided breast cancer RT for all breast
cancer survivors in 5–10 years to screen for radiation in-
duced heart disease [42].
Conclusions
The elevation on hscTnT levels suggests that adjuvant
RT causes subclinical myocardial damage in patients
with left-sided breast cancer. As the increase in hscTnT
associates with increased cardiac radiation doses all ef-
forts should be made to keep the radiation to the heart
as low as possible. Whether these acute subclinical
changes in echocardiography increase the risk of exces-
sive long-term cardiovascular morbidity or mortality in
our patients will be addressed in the later follow-up.
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